Floatz logo

Pamiparib

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

180 Active assets in the For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB

View all 50 →

Same molecule, other indications

Pamiparib is also rated in:

ovarian cancerDormant
B
Indicative ·
58 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
58 / 100
View asset →
grade II gliomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →